STRATASYS LTD

Their core work

Stratasys is a global leader in polymer 3D printing and additive manufacturing systems, headquartered in Israel. Within H2020, they contribute industrial-grade multi-material inkjet printing capabilities to research consortia — from nanoparticle-enhanced digital materials and microstructure-level design to bioprinting implants and ceramic scaffolds. Their role is typically that of a technology provider who brings commercial printing platforms and deep materials expertise into academic-led projects, enabling partners to push additive manufacturing into new application domains like biomedical implants, fashion, and appearance reproduction.

What they specialise in

How they've shifted over time

Stratasys entered H2020 in 2015 with DIMAP, focused squarely on advancing core 3D printing materials — nanoparticle-enhanced digital materials for robotics applications. From 2018 onward, their participation broadened significantly into application domains: fashion (REFREAM), visual appearance science (ApPEARS), microstructure engineering (ADAM^2), and biomedical implants (INKplant). The trajectory shows a company moving from "better printing materials" toward "printing as a platform for diverse industries," particularly healthcare and creative sectors.

Stratasys is expanding from core materials R&D into high-value application verticals — especially bioprinting and medical devices — making them an increasingly relevant partner for health-sector consortia needing industrial printing infrastructure.

How they like to work

Stratasys never coordinates H2020 projects — they join as an industrial participant or third party, contributing their printing technology and materials expertise to consortia led by others. With 61 unique partners across 14 countries in just 5 projects, they operate in large, diverse consortia rather than tight recurring partnerships. This profile suggests they are a sought-after industrial partner whose equipment and know-how are brought in to validate research concepts on commercial-grade platforms.

Broad European network spanning 61 unique partners across 14 countries, built through participation in large research consortia. As an Israeli company, their consistent presence in EU projects reflects strong integration into the European research ecosystem despite being a non-EU entity.

What sets them apart

Stratasys is one of very few globally recognized commercial 3D printing companies active in H2020 research consortia. Unlike university labs or research institutes, they bring production-ready multi-material inkjet technology — meaning research results can be validated on the same platforms used in industry. For consortium builders, partnering with Stratasys provides immediate access to industrial-scale additive manufacturing and a credible path from research to real-world application.

Highlights from their portfolio

• DIMAP
  Largest single EC contribution (EUR 799,688) and Stratasys's entry into H2020, focused on nanoparticle-enhanced 3D printing materials for robotics.
• INKplant
  Represents Stratasys's push into biomedical manufacturing — hybrid multi-material fabrication of next-generation implants using ceramic and biomaterial inks.
• ApPEARS
  MSCA training network where Stratasys contributed as a third-party expert on appearance reproduction, connecting printing science with metrology and colour research.